1. Introduction {#sec1}
===============

Alzheimer's disease (AD) is the most common cause of dementia in adults, resulting in a disorder of cognition and memory due to neuronal stress and eventuating in cell death. Current research indicates that mitochondrial and synaptic dysfunction is an early pathological feature of an AD affected brain.^[@ref1]−[@ref5]^ Mitochondrial amyloid-β (Aβ) accumulation in synaptic mitochondria has been shown to impair mitochondrial structure and function. Aβ accumulation also has been shown to influence calcium homeostasis, energy metabolism, membrane potential, membrane permeability transition pore (mPTP), mitochondrial dynamics, respiration, and oxidative stress.^[@ref6]−[@ref11]^ Preventing and/or halting AD at its earliest stages may be possible by suppressing Aβ-induced mitochondrial toxicity.^[@ref12]^ Blocking Aβ production or developing Aβ inhibitors are two possible approaches. Other strategies might include developing inhibitors that block the clipping action of secretases,^[@ref13]−[@ref20]^ compounds that interfere with Aβ oligomerization,^[@ref21]−[@ref23]^ and "passive vaccines" designed to clear amyloid directly.^[@ref13]^ To date, none of these approaches have been shown to dramatically improve AD symptoms or protect brain cells and no drugs have entered clinical trials due to concerns about side effects. Because AD is a multifaceted disease and its molecular biology is poorly understood, multitargeted approaches for AD treatment should be more effective.

Cyclophilin D (CypD), a peptidyl prolyl isomerase F, resides in the mitochondrial matrix and associates with the inner mitochondrial membrane during the mitochondrial membrane permeability transition. CypD plays a central role in opening the mPTP leading to cell death. The level of CypD was significantly elevated in neurons in AD-affected regions. We have shown that CypD forms a complex with Aβ (CypD--Aβ) that is present in the cortical mitochondria of AD brain and transgenic mice overexpressing human mutant form of amyloid precursor protein and Aβ (Tg mAPP). Surface plasmon resonance (SPR) has been used to show a high binding of recombinant CypD protein to Aβ. When CypD was not present, Aβ-mediated mitochondrial and synaptic dysfunction was reduced.^[@ref6],[@ref24]^ Although the precise role of Aβ in mitochondria is not yet defined, reports illustrate that an interaction between mitochondrial Aβ and mitochondrial proteins, such as CypD, exacerbates mitochondrial and neuronal stress in transgenic AD mouse models.^[@ref6],[@ref8],[@ref24],[@ref25]^ These reports support the use of CypD a potential target for drug development in the treatment of AD. Blockade of CypD protects against Aβ- and oxidative stress-induced mitochondrial and synaptic degeneration and improves mitochondrial and cognitive function. To date, the most specific inhibitor of the mPTP is cyclosporin A (CsA), which acts by inhibiting the peptidyl-prolyl cis--trans isomerase (PPIase) activity of CypD.^[@ref26]−[@ref28]^ Unfortunately, CsA lacks clinical significance because of its immunosuppressive effect by inhibiting calcinurin (a calcium dependent protein phosphatase) and its inability to pass through the blood--brain barrier (BBB). Several CsA derivatives have therefore been developed, including *N*-Me-Ala-6-cyclosporin A and *N*-Me-Val-4-cyclosporin, which both lack the unfavorable immunosuppressive effects but are still potent inhibitors of PPIase activity of CypD, thereby antagonizing mPTP opening and apoptosis induction.^[@ref29],[@ref30]^ Recently, Sanglifehrin A (SfA) and antamanide (AA) have been produced for inhibition of mPTP but lack significance as therapeutic molecules due to severe side effects including neurotoxicity, hepatotoxicity, nephrotoxicity, and poor permeability through the BBB.^[@ref31],[@ref32]^ Although Guo et al. have synthesized small molecule quinoxaline derivatives that inhibit the calcium-induced mPTP opening,^[@ref33]^ their effects on mPTP require re-evaluation. Other currently available CypD inhibitors have disadvantages, such as low solubility, poor infiltration of the blood-brain barrier, high toxicity, and low cell permeability.

The present study constructed a 2D quantitative structure--activity relationship (QSAR) and 3D ligand-based pharmacophore model from a training set of 40 compounds. This training set was then used to predict the inhibitory activity of a test set of 20 newly designed molecules. Validity of the QSAR model was indicated by linearity of the correlation, root-mean-square error (RMSE), and the correlation factor (*R*^2^). The pharmacophore model was used to select hits for docking studies from the test set. The docking studies of test set inhibitors with CypD were carried out to determine their binding affinity differences. Reliable models with respect to binding affinity and compound selectivity discrimination were obtained in this manner. Here, we report the design, synthesis, characterization (including three crystal structure determinations), and modeling studies for novel small-molecule CypD inhibitors based on new 4-aminobenzenesulfonamide and tetrahydropyrimidine scaffolds. Molecular docking can be used to interpret the efficacy of the novel molecules to inhibit CypD PPIase activity and hopefully indicate those that may be useful as drugs for the treatment and management of AD.

2. Materials and Methods {#sec2}
========================

In silico Study {#sec2.1}
---------------

All in silico studies were performed using Molecular Operating Environment (MOE), MOE2013.08.

QSAR Study {#sec2.2}
----------

The 3D models were built for all the compounds, and the energy was minimized to a root mean square (RMS) gradient of 0.01 kcal/mol and an RMS distance of 0.1 Å. MOE 2D-QSAR models were utilized for the 20 newly designed molecules, and these are the *test* compounds. A previously reported set of 40 molecules was used as the *training* set.^[@ref34]−[@ref36]^ The QSAR model was constructed for the *training* set of 40 compounds from their predicted QSAR descriptors (SlogP, density, molar refractivity, molecular weight, atomic polarizability, logP(o/w), logS, polar surface area, van der Waals volume, and radius of gyration). The \$PRED descriptor was considered as a dependent variable and activity field; the remaining descriptors are independent. Regression analysis was conducted and performed; the RMSE and *R*^2^ values were derived from the fit of \$PRED values vs SlogP. This QSAR model was applied to validate and evaluate the predicted activities and the residuals of the training set.

A correlation plot was constructed taking the predicted (\$PRED) values on (*X*-axis) and the predicted IC~50~ activities on (*Y*-axis). The outliers showing the Z-score above 1.5 are eliminated from this plot. The predicted (\$PRED) values of the 20 test set compounds were evaluated using the QSAR fit constructed from training set QSAR model. RMSE and *R*^2^ values were defined for the test set compounds by performing regression analysis. All the descriptors were subjected to pruning, and the optimum set of molecules was selected. The "QuaSAR-Contingency" application of MOE was used to identify the best molecules in the data set. A graphical 3D scatter plot was constructed from the first three principal components (PCA1, PCA2, and PCA3).

Pharmacophore Generation {#sec2.3}
------------------------

A Pharmacophore model was generated where the databases of 3D conformations was filtered based on the positions of annotation points derived from each of the conformations. A pharmacophore query was created from the training set molecules by considering annotation points such as aromatic center, H-bond donors and acceptors, and hydrophobic centroids of the molecule. This query was searched against the database of test set molecules to identify the similar pharmacophore model among them and separate the active compounds from the rest of the database. After the primary search, the query was subjected to refinement by excluding the external volumes that were not matching to the query and eliminating them from the search. The test data set conformations found to be having similar pharmacophore models were aligned for clear visualization.

Molecular Docking with CypD^[@ref37],[@ref38]^ {#sec2.4}
----------------------------------------------

### Preparation of CypD Protein {#sec2.4.1}

The 3D coordinates of CypD were obtained from Protein Data Bank (PDB ID: 2BIT) and loaded into MOE. The water molecules and heteroatoms were eliminated, and polar hydrogens were added. A temperature of 300 K, and salt concentration of 0.1 and pH 7 was specified in implicit solvated environment to carry out the protonation process. Then, the structure was energy-minimized in the MMFF94x force field to an RMS gradient of 0.05. The energy minimized conformation of CypD was then subjected to a 10 ns molecular dynamic simulations at a constant temperature of 300 K, heat time of 10 ps, and temperature relaxation of 0.2 ps.

The CypD structure was searched against the Blast-P similarity search tool against the PDB and the similar binding domains were identified. The identified residues (residues His 54, Arg 55, Phe 60, Gln 111, Phe 113, and Trp 121) were correlated with previously reported binding site of Cyp-D where Cyclisporin-A was bound.^[@ref39]^ All the 20 novel molecules were docked as database into the predicted binding domain, and 30 conformations were generated for each molecule in the CypD binding site. Among them the conformation with the lowest docking score was chosen to study the binding orientations of the ligands and each complex was assessed and ranked by the London Δ*G* energy scoring function.^[@ref12],[@ref40]^

Chemistry {#sec2.5}
---------

### Synthesis {#sec2.5.1}

#### General Procedure for the Synthesis of Compounds **4a**--**s** {#sec2.5.1.1}

A solution of ethyl/methyl acetoacetate (1 mmol), urea/thiourea (1 mmol) and ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate (1 mmol) in ethanol (10 mL) was heated under reflux (78--80 °C) in the presence of polyphosphoric acid (3.3 mol %) for 12 h under an inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate, 1:1 v/v). After being concentrated under vacuum at 50 °C, the reaction mixture was cooled to room temperature, poured into crushed ice (10 g), and stirred for 5--10 min. The solid that separated was filtered under reduced pressure and washed with ice-cold water (20 mL) before recrystallizing from hot ethanol to afford products **4a**--**s**.

#### General Procedure for the Synthesis of Compounds **6a**--**s** {#sec2.5.1.2}

To a solution of ethyl 6-methyl-4-(3-nitrophenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (**4a**) (1 mmol) in ethyl acetate (5 mL), tetrahydrofuran (2.5 mL) and substituted 1-bromo-4-phenyl (1 mmol) were added to this solution, and the reaction mixture was refluxed for 8--12 h at room temperature. The progress of the reaction was monitored by thin layer chromatography (TLC; dichloromethane:ethylacetate 1:1). Solvent was then removed under reduced pressure to give the crude product which was recrystallized from methanol to give a pure product **6a**. Related reactions were used to convert **4b**--**4s** into **6b**--**6s**. Compounds **6n**, **6o**, and **6p** were synthesized according to our published paper and spectral data (IR, NMR, and HRMS) of previously known compounds were identical with those reported in the literature.^[@ref40]^

#### Synthesis of 2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-*N*-(4-sulfamoylphenyl) Thiazole-5-carboxamide (**9**) {#sec2.5.1.3}

A solution of 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid (**7**) and thionyl chloride was stirred in dry toluene for 30 min in the presence of a catalytic amount of dimethylformamide. A clear solution resulted when the reaction temperature was slowly increased to 90--95 °C and continuously stirred for 3 h. Acid chloride formation was monitored by TLC (methylene dichloride:methanol 9:1). After completion, the reaction mixture was slowly cooled to room temperature and then concentrated at ambient temperature to give a white residue. This was dissolved in acetonitrile (20 mL), 4-aminobenzenesulfonamide (**8**) was added, and the solution was stirred for 4 h at 75 °C. This produced a solid that was separated by filtration, washed with acetonitrile (10 mL), and further washed with ice-cold water (10 mL) before recrystallizing from ethanol to afford pure compound **9**.

#### Crystal Data and Structure Determination of the Synthesized Compound {#sec2.5.1.4}

Colorless single-domain crystals of ethyl 5-(4-hydroxyphenyl)-7-methyl-3-phenethyl-5*H*-thiazolo\[3,2-a\]pyrimidine-6-carboxylate (**6n**), ethyl 5-(4-fluorophenyl)-7-methyl-3-phenethyl-5*H*-thiazolo\[3,2-*a*\]pyrimidine-6-carboxylate (**6o**), and 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-*N*-(4-sulfamoylphenyl) thiazole-5-carboxamide (**9**) suitable for single-crystal X-ray diffraction studies were grown from methanol. Crystallographic data and refinement results are summarized in Tables [3](#tbl3){ref-type="other"} and [4](#tbl4){ref-type="other"}. Full hemispheres of redundant diffracted intensities were measured at 100(2) K for single-domain specimens of all three compounds using 2--6 s frames and ω- or ϕ-scan widths of 0.50°. Measurements were made with monochromated Cu Kα radiation (λ= 1.54178 Å) on a Bruker Proteum single crystal diffraction system having dual charge-coupled device (CCD) detectors sharing a Bruker MicroStar microfocus rotating anode X-ray source operating at 45 kV and 60 mA. Data for **6n** and **6o** were collected with a Platinum 135 CCD equipped with Helios high-brilliance multilayer optics and data for **9** were collected with an Apex II CCD detector equipped with Helios multilayer optics. Sample-to-detector distances of 80 mm (**6o**, **6p**) and 50 mm (**9**) were used to collect data. Lattice constants for each crystal were determined with the Bruker SAINT software package using peak centers for 9843--9875 reflections. Integrated reflection intensities were produced for all structures using the Bruker program SAINT, and the data were corrected empirically for variable absorption effects using equivalent reflections. The Bruker software package SHELXTL was used to solve the structure using "direct methods" techniques. All stages of weighted full-matrix least-squares refinement were conducted using *F*~o~^2^ data with the SHELXTL v2010.3-0 software package.

The final structural models for all three structures incorporated anisotropic thermal parameters for all non-hydrogen atoms and isotropic thermal parameters for all hydrogen atoms. All hydrogen atoms for **6o** and **6p** were located in a difference Fourier and then included in the structural model as individual isotropic atoms whose parameters were allowed to vary in least-squares refinement cycles. Most of the hydrogen atoms for **9** were also located from a difference Fourier and included in the structural model as individual isotropic atoms whose parameters were allowed to vary in least-squares refinement cycles. The asymmetric unit for **9** contains two crystallographically independent molecules. The isopropyl group of the first molecule in **9** is disordered with two preferred orientations about the C(13)--C(14) bond. The minor (29%) orientation \[atoms labeled with a prime (′)\] was restrained to have bond lengths and angles similar to the major (71%) orientation. When parameters for some of the hydrogen atoms in **9** refined to unreasonable values, they were fixed at idealized sp^2^- or sp^3^-hybridized positions and their isotropic thermal parameters were fixed at values equal to 1.20 (nonmethyl) or 1.50 (methyl) times the equivalent isotropic thermal parameter of the carbon atom to which they were covalently bonded. Five methyl groups for compound **9** were eventually incorporated into the final structural model as rigid groups (using idealized sp^3^-hybridized geometry and a C--H bond length of 0.98 Å) that were allowed to rotate freely about their C--C bonds in least-squares refinement cycles. Two hydrogens bonded to sp^2^-hybridized carbons and one bonded to an sp^3^-hybridized carbon were eventually placed at idealized positions with C--H bond lengths of 0.95 or 1.00 Å and isotropic thermal parameters fixed at values 1.20 times the equivalent isotropic thermal parameter of the carbon atom. The isotropic thermal parameter of H(48) was also fixed at a value 1.20 times the equivalent isotropic thermal parameter of C(48).

3. Results and Discussion {#sec3}
=========================

Novel CypD Inhibitor Design {#sec3.1}
---------------------------

To create a novel drug for Alzheimer's treatment, multiple compounds were designed and synthesized and their capacity to inhibit CypD activity was predicted by QSAR and molecular docking studies. QSAR analysis has been used extensively as an aid in the design of novel and reactive molecules. Preliminary structure--activity relationship (SAR) studies revealed that the pyrimidine moiety is required for the inhibition of CypD activity and the presence of *5H*-thiazolo-\[3,2-*a*\]pyrimidines provides the basic functionality necessary to achieve binding in the CypD active site. These studies are further validated by the fact that pyrimide derivatives have also been widely used in the treatment of AD at various stages.^[@ref41]−[@ref44]^ In particular, pyrimides have shown a remarkable ability to enhance permeation across biological membranes. Many derivatives have therefore been constructed and tested using virtual docking methods.^[@ref42]^ The goal of our current research is to synthesize drugs that inhibit CypD activity and possibly provide enhanced viability by increasing the number of aromatic substituents on the basic pyrimidine and sulfonamide cores. *5H*-Thiazolo\[3,2-*a*\]pyrimidines were designed to incorporate significant intramolecular flexibility by linking polar groups having highly favorable enthalpic interactions with conserved enzyme residues in the CypD binding site.

QSAR Study {#sec3.2}
----------

Three-dimensional structures were built for all twenty test compounds (**6a**--**s** and **9**) and optimized in the molecular operating environment (MOE). Molecular dynamics simulations were carried out for each compound individually and the stabilized conformations of the compounds were used to determine the molecular descriptors along with the application of Lipinski rule-of-five. Fifteen of the 20 molecules were predicted to have *superior* drug like properties, i.e. they satisfied all five Lipinski rules. The remaining five should have *excellent* drug-like properties since they satisfied four of the five Lipinski criteria; these five all had logP values between 5.06 and 5.94 (Table [1](#tbl1){ref-type="other"}). The molecular descriptors of the present molecules are in optimal ranges with 15 of 20 compounds *totally* satisfying the Lipinski rule-of-five and the remaining 5 nearly satisfying the rules with LogP values that were slightly above the Lipinski limiting value of 5.00. A linear correlation plot resulted from the regression analysis for the *training* set of 40 compounds (Figure [1](#fig1){ref-type="fig"}) when a single outlier was eliminated. The model exhibited excellent linearity \[\$PRES = 0.297(IC~50~) + 2.978\], with RMSE = 0.982 and *R*^2^ = 0.872. The correlation plot for the QSAR model with the independent set of 20 newly designed test compounds was quite reasonable given the limited number of compounds in the training set. This was taken as an indication for the validity of applying the QSAR model. The resultant correlation regression analysis plot showed a perfect linear relationship for the final *test* data set \[\$PRES = 0.958(IC~50~) + 0.169\], with RMSE = 0.862 and *R*^2^ = 0.793 (Figure [2](#fig2){ref-type="fig"}).

A principal component analysis using the first three PCA eigenvectors included 98% of the variance. All the data values were found to lie in the range of −3 to +3. Each spot in the plot represents a molecule that is color coded by IC~50~ activity (Figure [3](#fig3){ref-type="fig"}). This could provide an addition criterion for compound selection.

![Linear correlation graph of measured IC~50~ values for 40 training set compounds with predicted values based on the calculated 2D QSAR model. The linearity of the trial set model is shown with the values of the error (RMSE) and correlation factor (*R*^2^).](ci-2014-000196_0001){#fig1}

![Linear correlation graph of measured IC~50~ values for 20 test set compounds with predicted values based on the calculated 2D QSAR model. The linearity of the trial set model is shown with the values of the error (RMSE) and correlation factor (*R*^2^).](ci-2014-000196_0002){#fig2}

![Plot of the principle component analysis (PCA) for the complete training set of 40 compounds. The first three principle eigenvectors are shown as PCA1, PCA2, and PCA3, and they constituted 98% of the variance. Coordinates for each of the 40 training compounds are indicated by a colored sphere.](ci-2014-000196_0003){#fig3}

###### Molecular Descriptors of Substituted Thiazolo\[3,2-*a*\]pyrimidine Derivatives (**6a**--**s**) and a Sulfonamide Derivative (**9**) from QSAR Study

  comp no.   molecular weight   logS      atomic polarizability   radius of gyration   SlogP   molar refractivity   surface area   volume    logP(o/w)   density
  ---------- ------------------ --------- ----------------------- -------------------- ------- -------------------- -------------- --------- ----------- ---------
  **6a**     437.492            --5.195   62.933                  3.808                4.051   11.840               228.972        394.500   4.464       0.801
  **6b**     439.483            --5.852   62.021                  3.835                4.485   11.669               190.875        391.625   4.925       0.813
  **6c**     480.539            --5.822   67.651                  3.738                4.868   12.309               141.269        412.625   4.894       0.775
  **6d**     408.486            --4.746   61.031                  3.763                3.222   11.507               201.689        379.125   3.917       0.772
  **6e**     410.477            --5.403   60.119                  3.765                3.655   11.336               150.986        377.875   4.378       0.784
  **6f**     460.541            --6.056   66.416                  3.799                4.133   12.288               159.793        409.750   4.856       0.739
  **6g**     410.485            --4.810   60.786                  3.763                4.395   11.274               208.095        380.000   4.598       0.782
  **6h**     412.476            --5.467   59.874                  3.761                4.828   11.103               157.814        378.750   5.059       0.794
  **6i**     462.540            --6.120   66.171                  3.806                5.306   12.055               158.940        407.375   5.537       0.747
  **6j**     452.009            --5.164   67.488                  4.018                2.765   12.603               241.371        423.500   3.604       0.791
  **6k**     454.522            --5.304   67.243                  3.911                3.174   12.330               186.172        413.625   4.307       0.804
  **6l**     396.459            --4.419   57.937                  3.717                2.832   11.045               222.368        364.375   3.576       0.782
  **6m**     398.450            --5.076   57.025                  3.693                3.265   10.874               179.439        360.000   4.037       0.794
  **6n**     449.531            --6.433   66.984                  4.155                5.461   12.499               189.877        419.750   5.725       0.771
  **6o**     420.533            --5.281   65.749                  4.071                5.258   12.000               144.647        407.375   5.482       0.741
  **6p**     422.524            --5.938   64.837                  4.079                5.692   11.830               95.952         404.375   5.943       0.752
  **6q**     480.585            --4.899   73.540                  4.235                3.860   13.154               204.436        452.625   4.414       0.761
  **6r**     407.514            --4.724   63.322                  4.098                3.601   11.721               182.292        394.125   4.060       0.746
  **6s**     465.550            --5.142   69.780                  4.285                3.145   12.817               216.144        434.375   3.747       0.767
  **9**      470.574            --6.735   66.797                  5.211                3.925   12.310               279.608        422.625   2.995       0.808

The pharmacophore model was derived for the test set compounds based on the specific features of the training set compounds. The test set compounds showed few similar and common pharmacophore features during the alignment. All of them are showing the common pharmacophore features like A1, A2, D6, R9, and R10 where the aromatic centers were matching to the maximum extent (Figure [4](#fig4){ref-type="fig"}). This implies that the QSAR data is in very good correlation with the activity of training set molecules.

![CypD pharmacophore model composed of the hydrophobic regions (Hyd) and H-bond donor/acceptor (Don&Acc). All the compounds are shown superimposed as occupying all four regions of the model.](ci-2014-000196_0004){#fig4}

Molecular Docking {#sec3.3}
-----------------

The ligand database that was developed form the total set of 20 test compounds that were used for docking with the known CypD receptor active site. Thirty ligand--receptor complex conformations were generated for each test compound, and the conformation with least docking score was considered for further analysis. The MOE interaction of all ligand molecules in the binding domain cavity was then analyzed by both London Δ*G* free energy approximations and Δ*E* interaction energies; this indicated that 10 of the 20 compounds should be ideal ligands. All 10 of these ligands (compounds **6e**, **6f**, **6h**, **6i**, **6k**, **6l**, **6n**, **6o**, **6p**, and **9**) exhibited good docking scores that were dominated by hydrogen bonding and salt-bridge formations with the binding domain of CypD (Table [2](#tbl2){ref-type="other"} and Figures [5](#fig5){ref-type="fig"}--[7](#fig7){ref-type="fig"}). Hydrophobic interactions were also observed to play a contributing role. These docking experiments indicated that the molecules are good enough to act as CypD inhibitors. Among all docking conformations, compounds **6e** and **6n** had the best least docking scores of −12.891 and −12.294 kcal/mol, respectively. Compounds **6f, 6p**, and **9** had the next best least docking scores with values for docking scores of −11.363, −11.134, and −11.074, respectively. Compound **9** was found to form an arene--arene π-stacking interaction with His 54.

![Compounds **6f**, **6o**,**6p**, and **9** are shown in their docked position within the 2BIT structure. The active site regions are indicated. The enzymatic triads are shown relative to the docked potential candidates.](ci-2014-000196_0005){#fig5}

![Binding site for active IC~50~ compounds **6f**, **6o**, and **9**. Two H-bonds to Asn 102 and Gln 63 make major contributions to the binding affinity for compound **6f** (left). Salt bridges to Lys 152 and Asn 71 and an H-bond to His 54 make major contributions to the binding affinity for compound **9** (right); H-bonding interactions and salt bridges are shown with dotted lines. The arene--arene π-stacking interaction between His 54 and H-bonding with Arg 82 compound **6o** is shown on the middle.](ci-2014-000196_0006){#fig6}

![2D Ligand interaction maps of compound **6f** (left), compound **6o** (middle), and compound **9** (right) binding to CypD.](ci-2014-000196_0007){#fig7}

###### Molecular Docking Interaction of 20 Trial Compounds against the CypD (2BIT) Active Site

  compd no[a](#t2fn1){ref-type="table-fn"}   docking score (kcal/mol)[b](#t2fn2){ref-type="table-fn"}   number of hydrogen bonds[c](#t2fn3){ref-type="table-fn"}   interacting residues of 2BIT[d](#t2fn4){ref-type="table-fn"}
  ------------------------------------------ ---------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------
  **6a**                                     --9.040                                                    3                                                          His 54, Val 56, Gln 63
  **6b**                                     --8.505                                                    arene--cationic/π interaction                              Arg 55
  **6c**                                     --8.640                                                    --                                                         --
  **6d**                                     --9.150                                                    2                                                          His 54, Gly 150
  **6e**                                     12.891                                                     2                                                          His 54, Gly 150
  **6f**                                     --11.363                                                   2                                                          Gln 63, Asn 102
  **6g**                                     --8.723                                                    3                                                          Arg 151, Thr 152, Thr 152
  **6h**                                     --10.014                                                   1                                                          Arg 151
  **6i**                                     --9.529                                                    --                                                         --
  **6j**                                     --11.134                                                   2                                                          Phe 53, Thr 152
  **6k**                                     --9.619                                                    --                                                         --
  **6l**                                     --9.206                                                    1                                                          Arg 151
  **6m**                                     --10.294                                                   2                                                          Thr 152, Thr 152
  **6n**                                     --10.363                                                   3                                                          Arg 151, Ser 149, Arg 55
  **6o**                                     --10.074                                                   arene--H interaction                                       Arg 82, His 54
  **6p**                                     --11.134                                                   arene--arene interaction                                   His 54
  **6q**                                     --8.314                                                    arene--cationic π-interaction                              Arg 151
  **6r**                                     --8.095                                                    1                                                          Arg 151
  **6s**                                     --9.332                                                    1                                                          Arg 55
  **9**                                      --11.074                                                   3, arene--arene π-interaction                              His 54, Lys 155, Asn 71

The novel CypD inhibitors.

Docking scores generated during MOE docking between the novel leads and CypD binding domain.

Number of hydrogen bonds formed between the CypD binding domain and the novel leads.

The interacting active site residues of CypD protein with the novel inhibitors in the ligand--receptor complex.

Chemistry {#sec3.4}
---------

On the basis of QSAR, pharmacophore modeling and molecular docking studies, 10 compounds (**6e**, **6f**, **6h**, **6i**, **6k**, **6l**, **6n**, **6o**, **6p**, and **9**) were selected for synthesis. Nine are pyrimidine derivatives, and the tenth is a sulfonamide derivative. These compounds were shown to have the best interactions with the CypD active site. They gave the lowest docking scores among all compounds considered and showed satisfactory QSAR and drug-like properties. These pyrimidine derivatives were all synthesized in refluxing ethanol by reacting aromatic aldehydes (**1**), methyl/ethyl acetoacetate (**2**), and thiourea (**3**) in the presence of polyphosphoric acid (PPA) (3.3 mol %) for 8--12 h to yield dihydropyrimidine derivatives **4e**, **4f**, **4h**, **4i**, **4k**, **4l**, **4n**, **4o**, and **4p**. Reaction progress was monitored by TLC (dichloromethane:ethyl acetate, 1:1 v/v). Spectral data (IR, NMR, and HRMS) of previously known compounds were identical with those reported in the literature. The intermediate dihydropyrimidines **4e**, **4f**, **4h**, **4i**, **4k**, **4l**, **4n**, **4o**, and **4p** were reacted with substituted aromatic 1-bromo compounds at reflux temperature for 6--12 h to obtain our target CypD inhibitors **6e**, **6f**, **6h**, **6i**, **6k**, **6l**, **6n**, **6o**, and **6p** as shown in Scheme [1](#sch1){ref-type="scheme"} and Table [3](#tbl3){ref-type="other"}. The chemical structures of the new compounds were confirmed by IR, ^1^H NMR, ^13^C NMR spectral, and HRMS; the spectral data are provided in the [Supporting Information](#notes-1){ref-type="notes"}. Structures for compounds **6o** (Figure [8](#fig8){ref-type="fig"} and Table [4](#tbl4){ref-type="other"}) and **6p** (Figure [9](#fig9){ref-type="fig"} and Table [4](#tbl4){ref-type="other"}) were further confirmed by single-crystal XRD.

![Synthetic Route for Small Molecule Pyrimidine Inhibitors of Human CypD](ci-2014-000196_0011){#sch1}

###### Representative Compounds

  entry    R                R^1^            R^2^      *n*  entry    R                R^1^   R^2^     *n*
  -------- ---------------- --------------- -------- ----- -------- ---------------- ------ -------- -----
  **6a**   3-NO~2~          4-OH            ethyl      1   **6k**   4-OH, 5OOCH~3~   4-F    ethyl    1
  **6b**   3-NO~2~          4-F             ethyl      1   **6l**   4-OH             4-OH   methyl   1
  **6c**   3-NO~2~          3,4-di chloro   ethyl      1   **6m**   4-OH             4-F    methyl   1
  **6d**   4-OH             4-OH            ethyl      1   **6n**   3-NO~2~          --     ethyl    2
  **6e**   4-OH             4-F             ethyl      1   **6o**   4-OH             --     ethyl    2
  **6f**   4-OH             3,4-di chloro   ethyl      1   **6p**   4-F              --     ethyl    2
  **6g**   4-F              4-OH            ethyl      1   **6q**   4-OH, 5OOCH~3~   --     ethyl    2
  **6h**   4-F              4-F             ethyl      1   **6r**   4-OH             --     methyl   2
  **6i**   4-F              3,4-di chloro   ethyl      1   **6s**   4-OH, 5OOCH~3~   --     methyl   2
  **6j**   4-OH, 500CH~3~   4-OH            methyl     1                                              

###### Crystal Data and Details of the Structure Determination for **6o** and **6p**

  ------------------------------------------ ----------------------------------------------- -----------------------------------------------
  identification code                        **6o**                                          **6p**
  empirical formula                          C~24~H~25~BrN~2~O~4~S                           C~24~H~24~BrF N~2~O~2~ S
  formula weight                             517.43                                          503.42
  temperature                                100(2) K                                        100(2) K
  wavelength                                 1.54178 Å                                       1.54178 Å
  crystal system                             monoclinic                                      monoclinic
  space group                                *P*2~1~/*c*                                     *P*2~1~/*c*
  unit cell dimenions                        *a* = 6.5365(7) Å α = 90°                       *a* = 14.7445(16) Å α = 90.000°
  *b* = 18.132(2) Å β = 95.327(2)°           *b* = 6.8046(7) Å β = 98.128(2)°                
  *c* = 18.855(2) Å λ = 90.000°              *c* = 22.826(2) Å λ = 90.000°                   
  volume                                     2224.9(4) Å^3^                                  2267.1(4) Å^3^
  *Z*                                        4                                               4
  density (calculated)                       1.545 g/cm^3^                                   1.475 g/cm^3^
  absorption coefficient                     3.687 mm^--1^                                   3.598 mm-1
  *F*(000)                                   1064                                            1032
  crystal size                               0.42 × 0.08 × 0.06 mm^3^                        0.17 × 0.06 × 0.03 mm^3^
  theta range for data collection            3.39--67.89°                                    6.79--67.90°
  index ranges                               --7 ≤ *h* ≤ 6, −21 ≤ *k* ≤ 21, −22 ≤ *l* ≤ 22   --17 ≤ *h* ≤ 17, −7 ≤ *k* ≤ 7, −22 ≤ *l* ≤ 27
  reflections collected                      13265                                           12782
  independent reflections                    3921 \[*R*~int~ = 0.026\]                       3934 \[*R*~int~ = 0.029\]
  completeness to theta = 66.00°             98.8%                                           98.3%
  absorption correction                      multiscan                                       multiscan
  max. and min transmission                  1.000 and 0.594                                 1.000 and 0.778
  refinement method                          full-matrix least-squares on *F*^2^             full-matrix least-squares on *F*^2^
  data/restraints/parameters                 3921/0/381                                      3934/0/377
  goodness-of-fit on *F*^2^                  1.085                                           1.065
  final *R* indices \[*I* \> 2sigma(*I*)\]   *R*~1~ = 0.027, *wR*~2~ = 0.075                 *R*~1~ = 0.027, *wR*~2~ = 0.069
  *R* indices (all data)                     *R*~1~ = 0.027, w*R*~2~ = 0.075                 *R*~1~ = 0.028, w*R*~2~ = 0.070
  largest diff. peak and hole                0.47 and −0.44 e^--^/Å^3^                       0.36 and −0.46 e^--^/Å^3^
  ------------------------------------------ ----------------------------------------------- -----------------------------------------------

![Crystal structure for HBr salt of **6o** showing 50% probability displacement ellipsoids and atom-numbering scheme.](ci-2014-000196_0008){#fig8}

![Crystal structure for HBr salt of **6p** showing 50% probability displacement ellipsoids and atom-numbering scheme.](ci-2014-000196_0009){#fig9}

Sulfonamide (**9**) was prepared by the reaction of Febuxostat (**7**) with thionyl chloride in the presence of a catalytic amount of *N*,*N*-dimethylformamide. The thionyl chloride reacted with **7** to form the corresponding acid chloride that then reacted with substituted 4-aminobenzenesulfonamide, in the presence of triethylamine in toluene, to give the corresponding sulfonamide derivative 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-*N*-(4-sulfamoylphenyl) thiazole-5-carboxamide (**9**) (Scheme [2](#sch2){ref-type="scheme"}). The progress of the reaction was monitored by TLC (dichloromethane:ethyl acetate 1:1 v/v). The chemical structure of the new compound was confirmed by elemental analysis, IR, ^1^H NMR, ^13^C NMR, and HRMS; the spectral data are provided in the [Supporting Information](#notes-1){ref-type="notes"}. The structure of compound **9** (Figure [10](#fig10){ref-type="fig"} and Table [5](#tbl5){ref-type="other"}) was further confirmed by single crystal XRD.

![Synthetic Route for Small Molecule Sulfonamide Inhibitor of Human CypD](ci-2014-000196_0012){#sch2}

![Crystal structure for compound **9** showing 50% probability displacement ellipsoids and atom-numbering scheme.](ci-2014-000196_0010){#fig10}

###### Crystal Data and Details of the Structure Determination for Compound **9**

  ------------------------------------------ -------------------------------------------------
  identification code                        **9**
  empirical formula                          C~44~H~44~N~8~O~8~S~4~
  formula weight                             941.11
  temperature                                100(2) K
  wavelength                                 1.54178 Å
  crystal system                             monoclinic
  space group                                *P*2~1~/*c*
  unit cell dimensions                       *a* = 17.0482(4) Å α = 90°
  *b* = 14.1161(4) Å β = 113.516(1)°         
  *c* = 19.9664(5) Å λ = 90°                 
  volume                                     4405.9(2) Å^3^
  *Z*                                        4
  density (calculated)                       1.419 g/cm^3^
  absorption coefficient                     2.513 mm^--1^
  *F*(000)                                   1968
  crystal size                               0.11 × 0.10 × 0.10 mm^3^
  theta range for data collection            2.83--69.85°
  index ranges                               --20 ≤ *h* ≤ 19, −17 ≤ *k* ≤ 16, −24 ≤ *l* ≤ 24
  reflections collected                      37842
  independent reflections                    8157 \[*R*~int~ = 0.029\]
  completeness to theta = 66.00°             99.6%
  absorption correction                      multiscan
  max and min transmission                   1.000 and 0.895
  refinement method                          full-matrix least-squares on *F*^2^
  data/restraints/parameters                 8157/9/741
  goodness-of-fit on *F*^2^                  1.055
  final *R* indices \[*I* \> 2sigma(*I*)\]   *R*~1~ = 0.057, w*R*~2~ = 0.156
  *R* indices (all data)                     *R*~1~ = 0.060, w*R*~2~ = 0.159
  largest diff. peak and hole                0.98 and −0.72 e^--^/Å^3^
  ------------------------------------------ -------------------------------------------------

Crystal Data and Structure Determination of the Synthesized Compounds {#sec3.5}
---------------------------------------------------------------------

Pyrimidine derivatives **6o** and **6p** and sulfonamide derivative **9** were each recrystallized from methanol to give colorless crystals suitable for single-crystal X-ray diffraction experiments. Crystallographic data are summarized in Table [3](#tbl3){ref-type="other"} for **6o** and **6p** and in Table [4](#tbl4){ref-type="other"} for **9**. The intensity data were collected at 100(2) K using monochromatic Cu Kα radiation (λ = 1.54178 Å) radiation on Bruker Proteum diffractometer that has two CCD detectors sharing a Bruker MicroStar microfocus rotating anode X-ray source operating at 45 mA and 60 kV. Nearly complete (98.3--99.6% to θ = 66.00°) redundant sets of unique data for **6o** and **6p** were collected with a Platinum 135 CCD detector equipped with Helios high-brilliance multilayer optics; similar data for **9** were collected with an Apex II CCD detector equipped with Helios multilayer optics. A crystal-to-detector distance of 80 mm was used for **6o** and **6p**, and a crystal-to-detector distance of 50 mm was used for **9**. The intensity data were processed using the Bruker suite of data processing programs (SAINT), and absorption corrections were applied using SADABS. The crystal structures were solved by direct methods and refined by full matrix least-squares refinement on *F*^2^ using SHELXL. Nonhydrogen atoms were modeled with anisotropic thermal parameters and hydrogen atoms were modeled with isotropic thermal parameters. All of the hydrogen atoms for **6o** and **6p** and most of the hydrogen atoms for **9** were refined as independent isotropic atoms after being located from difference Fouriers. The remaining hydrogen atoms for **9** were fixed at idealized positions.

4. Conclusion and Future Direction {#sec4}
==================================

In this study, we report the design, synthesis, docking, 2D QSAR, and pharmacophore studies for a series of 20 CypD inhibitors, 10 of which were synthesized. Single crystal X-ray structures are reported for three of these. Our molecules exhibited strong binding affinity with the CypD receptor during the molecular docking process. 2D QSAR and 3D pharmacophore studies have been used as tools for selecting active drug candidates from a large volume of prospective compounds designed to incorporate desirable structural features. We hope these results demonstrate the ability of these procedures to accurately predict active drug candidates. The docking, 2D QSAR, and pharmacophore studies indicate that 10 (**6e**, **6f**, **6h**, **6i**, **6k**, **6l**, **6n**, **6o**, **6p**, and **9**) of the 20 candidate compounds should be superior inhibitors of CypD. We hope to use and refine this as an effective strategy for developing even more potent CypD inhibitors for use in treating Alzheimer's disease.

Spectroscopic data for synthesized compounds (^1^H, ^13^C, NMR, HRMS), interaction of remaining 17 novel inhibitors with CypD active site and detailed crystallographic experimental details with structural tables. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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CypD

:   Cyclophilin D

mPTP

:   mitochondrial membrane permeability transition pore

ACh

:   acetylcholine

AD
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SPR

:   surface plasmon resonance

Aβ

:   amyloid beta

QSAR

:   quantitative structure--activity relationship

BBB
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SAR
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CNS

:   central nervous system
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:   root mean square error

PCA

:   principle component analysis

PDB
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:   the Merck molecular force field
